Boehringer and AnGes sign manufacturing agreement for HGF gene therapy product

Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing

Boehringer Ingelheim has announced the signing of a contract development and manufacturing agreement with AnGes for the drug substance of AnGes' investigational treatment for Peripheral Arterial Disease (PAD).

This milestone follows AnGes' recent announcement on August 8, 2025 confirming the completion of clinical trials and its intention to proceed with a Biologics License Application (BLA). At that time, AnGes also indicated that final arrangements for a supply agreement were underway.

With the agreement for contract development and manufacturing of the product’s drug substance by Boehringer Ingelheim now in place, both companies will continue their collaboration toward regulatory approval and future patient access.

Boehringer Ingelheim BioXcellence, the biopharmaceutical contract manufacturing branch of the corporation, serves as a contract development and manufacturing organization (CDMO) for AnGes, responsible for manufacturing and supplying the active pharmaceutical ingredient of the Hepatocyte Growth Factor (HGF) gene therapy product. The plasmid DNA molecule has been manufactured using proprietary microbial technology in E. coli at Boehringer's site in Vienna, Austria, since the collaboration for clinical trial supply began nearly 20 years ago.